Table 2.
FDA-approved medications for MM from 2014 to 2019.
| Drug | Year | Treatment | Adverse Effects | Name and NCT Number |
Refs. |
|---|---|---|---|---|---|
| Panobinostat | 2015 | RRMM | pneumonia, diarrhea, arrhythmias, hypophosphatemia and hypokalemia, ECG change, thrombocytopenia, neutropenia fatigue, and sepsis | PANORAMA1 NCT01023308 |
[69] |
| Carfilzomib | 2015 | RRMM | CVE, VTE, ARF, pulmonary toxicities, hypertension, and thrombocytopenia | ASPIRE NCT01080391 |
[70] |
| Daratumumab | 2015 | RRMM | fatigue, nausea, back pain, pyrexia, URTI, cough, IRs, lymphopenia, neutropenia, anemia, and thrombocytopenia | SIRIUS NCT01985126 |
[71] |
| Ixazomib | 2015 | RRMM | diarrhea, constipation, thrombocytopenia, PSN, nausea, peripheral edema, vomiting, and back pain | TOURMALITOURMALINE NCT01564537 |
[47] |
| Elotuzumab | 2015 | RRMM | ARF, pneumonia, nasopharyngitis pyrexia, anemia, pulmonary embolism, and PSN | ELOQUENT-2 NCT01239797 |
[72] [73] |
| Daratumumab | 2016 | RRMM | URTI, cough, diarrhea, fatigue, nausea, pyrexia, muscle spasm, and dyspnea, neutropenia, anemia | POLLUX NCT02076009 |
[74] |
| Daratumumab | 2016 | RRMM | URTI, IRs, diarrhea, peripheral edema, Neutropenia, and thrombocytopenia, anemia | CASTOR NCT02136134 |
[75,76] |
| Daratumumab | 2019 | NTE NDMM |
IRs, URTI, diarrhea, constipation, peripheral edema, nausea, fatigue, asthenia, dyspnea, pyrexia, muscle spasms, and PSN | MAIA NTC02252172 |
[66,77,78] |
| Selinexor | 2019 | RRMM | Thrombocytopenia, fatigue, nausea, anemia, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and URTI | STORM KCP-330-012 NCT02336815 |
[79,80] |
| Daratumumab | 2019 | TE NDMM |
IRs, PSN, constipation, asthenia, nausea, neutropenia, thrombocytopenia, peripheral edema, pyrexia and paresthesia | CASSIOPEIA NCT02541383 |
[81] |
NDMM: newly diagnosed multiple myeloma; RRMM: relapsed/refractory multiple myeloma; NTE: non-transplant-eligible; TE: transplant eligible; ORR: overall response rate; Vd: bortezomib, dexamethasone; PAN-Vd: panobinostat, bortezomib, dexamethasone; Rd: lenalidomide, dexamethasone; KRd: carfilzomib, lenalidomide, dexamethasone; DVd: daratumumab, bortezomib, dexamethasone; DRd: daratumumab, lenalidomide, dexamethasone; IRd: ixazomib, lenalidomide + dexamethasone; VTd: bortezomib, thalidomide, and dexamethasone; DVTd: daratumumab, bortezomib, thalidomide, dexamethasone; ERd: elotuzumab, lenalidomide, dexamethasone; Sd: selinexor, dexamethasone; m: months; PFS: progression-free survival; NR: Not Reached; URTI: Upper respiratory tract infection; PSN: Peripheral sensory neuropathy; IRs: Infusion reactions; VTE: venous thromboembolic events; CVE: Cardiovascular events, ARF: acute renal failure.